– Findings reported today in the journal Lancet Infectious Diseases– Study shows synergistic immunological response generated by M2SR and Fluzone High…
SCOTTSDALE, Ariz., July 11, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that…
SHELTON, CT / ACCESSWIRE / July 11, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader…
Sapiens' expanded offering maximizes business value for MPL insurers, supporting growth and retention ROCHELLE PARK, N.J., July 2, 2024…
Recommendation based on data from the Phase 1 and pivotal Phase 2 trials demonstrating robust and durable response rates in…
SEATTLE, June 20, 2024 /PRNewswire/ -- Even as the role of wildlife in disease outbreaks is increasingly recognized, our ability to…
REDWOOD CITY, Calif., June 19, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company…
Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of…
– Company also receives short extension of its credit agreement until July 31, 2024 –MINNEAPOLIS, June 17, 2024 (GLOBE NEWSWIRE)…
At 14-months median follow-up in the pivotal trial, 50% of patients achieved a complete response or better and a 71%…